SEC Form 4/A · accession 0001019056-16-001557
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Jeffrey G. Lamothe
Officer — SVP, CFO and Treasurer
Period of report
Aug 3, 2016
Accepted (ET)
Sep 27, 2016 · 3:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001671584
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF4,F2,F3 | — | Aug 3, 2016 | A | 50,680 | A | — | — | Common Stock | 50,680 | 104,994 | D |
| Stock Option (right to buy)F5,F6,F7,F8 | — | holding | — | — | — | — | — | Common Stock | 108,532 | 108,532 | D |
Explanation of responses
- F1This report has been amended to reflect that the reporting person does not now, nor has he ever, held any shares of the Issuer's common stock.
- F2Each RSU represents the right of the reporting person to receive one share of common stock of the Issuer.
- F3This report has been amended to reflect that the RSUs will vest in two equal installments on February 3, 2017 and February 3, 2018.
- F4This report has been amended to reflect the 35,451 RSUs that were originally issued by Emergent BioSolutions, Inc. ("Emergent") and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed by the Issuer under its Converted Equity Awards Incentive Plan.
- F5This report has been amended to include the stock options that were originally issued by Emergent and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed under the Issuer's Converted Equity Awards Incentive Plan.
- F637,736 of the Reporting Person's stock options are exercisable at an exercise price of $2.47 per share; 26,996 of the Reporting Person's stock options are exercisable at an exercise price of $2.55 per share; and 43,800 of the Reporting Person's stock options are exercisable at an exercise price $2.97.
- F737,736 of the Reporting Person's stock options fully vest on March 10, 2017; 26,996 of the Reporting Person's stock options vest as follows: 13,504 on March 10, 2017 and 13,492 on March 10, 2018; and 43,800 of the Reporting Person's stock options vest in three equal installments on March 1, 2017, March 1, 2018 and March 1, 2019.
- F837,736 of the Reporting Person's stock options expire on March 10, 2021; 26,996 of the Reporting Person's stock options expire on March 9, 2022; and 43,800 of the Reporting Person's stock options expire on February 28, 2026.